HOME >> BIOLOGY >> NEWS
Ohio researcher receives national award

Pioneered addition of fluoride to toothpaste

M. David Francis of Wyoming, Ohio, will be honored on August 20 by the world's largest scientific society for his pioneering role in developing fluoride additives for toothpaste, bone-strengthening pharmaceuticals and other medical products. He will be designated one of 12 Heroes of Chemistry by the American Chemical Society at its 220th national meeting, in Washington, D.C.

"My original work was in dentistry," said Francis, a physical biochemist who began a career with Proctor & Gamble in 1952. Products based on his findings include two of the most widely used toothpastes: Advanced Formula Crest and Tartar Control Crest.

In nominating him for the award, Joel Shulman, P&G's external affairs manager, wrote: "Dr. Francis' research on the chemistry of tooth enamel structure and formation, and on the mechanism by which the fluoride ion interferes with the destruction of tooth enamel and dentin, played a role in the widespread adoption of fluoride therapies throughout the United States and the world." Shulman noted that cavities among U.S. children have dropped 80 percent since 1967.

"When we found out how [such additives] operated on dental enamel, it was a small jump to see the same thing happen with bone," said Francis. His efforts led to new compounds called bisphosphonates, which treat a variety of bone diseases.

The body constantly recycles its skeletal structure, breaking down old bone tissue and replacing it with new. In disorders like Paget's disease, however, resorption and formation are accelerated, and bones become soft, porous and misshapen.

One of Francis' discoveries, marketed as Didronel, bonds to bone surfaces to slow bone resorption and allow for normal formation. It is approved in 26 countries to help stop age-related bone loss, or osteoporosis. A related product, Osteoscan, is used to delineate patients' bone structure. The bisphosphonate molecule carries a ra
'"/>

Contact: Christina Curtin
c_curtin@acs.org
202-872-4400
American Chemical Society
17-Aug-2000


Page: 1 2

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. University of Alberta researcher looks for clues to mysterious disease
4. $7.5 Million grant to Yale researchers for role of viruses in cancer
5. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
6. Joslin researchers clarify mechanisms for beta-cell formation
7. Pioneering AIDS researcher to speak at UH
8. Defensive action by influenza viruses demonstrated by Hebrew university researcher
9. Virginia Tech researchers to release findings on Smith River Project
10. Molecular motor myosin VI moves hand over hand, researchers say
11. Tiny molecules have big potential as cancer drugs, Stanford researcher believes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology:
Cached News: